NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

NCT04055428 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus
Cardiovascular Diseases
Insulin Sensitivity/Resistance
Metabolic Disease
Natriuretic Peptides
Metabolism
Energy Expenditure

Interventions

DRUG: Sacubitril, Valsartan 97-103 mg Oral Tablet
DRUG: Valsartan 160 mg
OTHER: Intravenous Glucose Tolerance Test
DIETARY_SUPPLEMENT: Standardized Meals
OTHER: Exercise capacity VO2 maximum determination

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]